What does treatment with radiopharmaceutical XOFIGO® mean?
It is a pharmacological method for treating prostate cancer using the radiopharmaceutical XOFIGO®. HIFU CLINIC Prostate Cancer Treatment Centre is the only medical centre in Poland offering privately paid treatment with a medicinal product XOFIGO®. This medicine contains an active substance, radium dichloride, Ra-223.
What does the therapy involve?
The medicinal product XOFIGO® is administered at 4 weeks intervals, as 6 injections. XOFIGO®, i.e., radium 223, reaches bones where cancer metastases are located, and emits short-range radiation destroying cancer cells without damaging bone marrow.
The radiopharmaceutical XOFIGO® should only be administered by personnel authorised to use formulations of this type, at designated clinical centres, and after Patient's health is examined by a qualified doctor.
Who is this therapy for?
This therapy is intended for Patients with bone metastatic castrate-resistant prostate cancer. At this stage cancer does not respond to treatment reducing levels of male sex hormones, and is characterised by symptomatic (e.g., pain) metastases to bones without signs of disease spreading to other organs.
How can I arrange the therapy?
Please contact us for consultation and confirming the need for the therapy using the free online consultation. We will gladly analyse your medical history and answer all your questions.
To arrange the treatment, please contact the Patient coordination department at: + 48 606 994 372 or by email: email@example.com.
The aim of the LRP therapy is to prevent further development of the disease through prostate resection.
The aim of this procedure is to restore man's ability to develop erection, e.g., after radical prostatectomy.